CLAIMS:

1. A crystalline form of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt, wherein the crystalline form is Form 1, and wherein the crystalline form has a purity of greater than 90%.

2. The crystalline form of claim 1, wherein the crystalline form has a powder X-ray diffraction pattern (PXRD) comprising one peak, in terms of 2θ (Cu Kα radiation source, wavelength of 1.5406Å), selected from those at 14.3± 0.2º, 17.5 ± 0.2º, and 18.0 ± 0.2º.

3. The crystalline form of claim 2, wherein the crystalline form has a powder X-ray diffraction pattern (PXRD) comprising peaks, in terms of 2θ, at 14.3± 0.2º, 17.5 ± 0.2º, and 18.0 ± 0.2º.

4. The crystalline form of claim 2, wherein the crystalline form has a powder X-ray diffraction pattern (PXRD) comprising peaks, in terms of 2θ, at 14.3± 0.2º, 17.5 ± 0.2º, 18.0 ± 0.2º, 23.4 ± 0.2º, and 24.7 0.2º.

5. The crystalline form of any one of claims 1 to 4, wherein the crystalline form has a ^{13}C ssNMR spectrum comprising peaks, in terms of chemical shifts, at 171.0 ± 0.2 ppm and 141.3 ± 0.2 ppm.

6. The crystalline form of any one of claims 1 to 5, wherein the crystalline form has a ^{15}N ssNMR spectrum comprising peaks, in terms of chemical shifts, at -339.9 ± 0.2 ppm and -223.4 ± 0.2 ppm.

7. The crystalline form of any one of claims 1 to 6, wherein the crystalline form has a ^{19}F ssNMR spectrum comprising one peak, in terms of chemical shifts, at -118.8 ± 0.2 ppm.

8. The crystalline form of any one of claims 1 to 7, wherein the crystalline form has a FT-Raman spectrum comprising one peak, in terms of wavenumbers (cm^{-1}), selected from those at 1371 ± 2 cm^{-1}, 430 ± 2 cm^{-1}, and 416 ± 2 cm^{-1}.

9. The crystalline form of any one of claims 1 to 8, wherein the crystalline form has a FT-Raman spectrum comprising peaks, in terms of wavenumbers (cm^{-1}), at 1371 ± 2 cm^{-1}, 430 ± 2 cm^{-1}, and 416 ± 2 cm^{-1}.

10. A pharmaceutical composition comprising a therapeutically effective amount of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt ("tris salt of Compound 1") and a pharmaceutically acceptable carrier, wherein at least 90% of the tris salt of Compound 1 is present as the crystalline form of any one of claims 1 to 9.

11. An amorphous form of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt, wherein the amorphous is Form 2, and wherein the amorphous form has purity greater than 90%.

12. The amorphous form of claim 11, wherein the amorphous form has a ^{13}C ssNMR spectrum comprising one peak, in terms of chemical shifts, selected from those at 174.0 ± 0.2 ppm, 143.9 ± 0.3 ppm, and 62.2 ± 0.3 ppm.

13. The amorphous form of claim 11, wherein the amorphous form has a ^{13}C ssNMR spectrum comprising peaks, in terms of chemical shifts, at 174.0 ± 0.2 ppm, 143.9 ± 0.3 ppm, and 62.2 ± 0.3 ppm.

14. The amorphous form of any one of claims 11 to 13, wherein the amorphous form has a ^{15}N ssNMR spectrum comprising peaks, in terms of chemical shifts, at -332.7 ± 0.8 ppm and -229 ± 1.0 ppm.

15. The amorphous form of any one of claims 11 to 14, wherein the amorphous form has a ^{19}F ssNMR spectrum comprising one peak, in terms of chemical shifts, at -116.3 ± 0.8 ppm.

16. The amorphous form of any one of claims 11 to 15, wherein the amorphous form has a FT-Raman spectrum comprising one peak, in terms of wavenumbers (cm^{-1}), selected from those at 1513 ± 2 cm^{-1}, 1278 ± 2 cm^{-1}, and 1378 ± 2 cm^{-1}.

17. A pharmaceutical composition comprising a therapeutically effective amount of 2-[(4-{6-[(4-Cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt ("tris salt of Compound 1") and a pharmaceutically acceptable carrier, wherein at least 50% of the tris salt of Compound 1 is present as the amorphous form of any one of claims 11 to 16.

18. A pharmaceutical composition comprising a therapeutically effective amount of 2-[(4-{6-[(4-Cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt ("tris salt of Compound 1") and a pharmaceutically acceptable carrier, wherein the tris salt of Compound 1 comprises the crystalline form of tris salt of Compound 1 of any one of claims 1 to 9 and the amorphous form of tris salt of Compound 1 of any one of claims 11 to 16.

19. Use of the crystalline form of tris salt of Compound 1 of any one of claims 1 to 9, or use of the amorphous form of tris salt of Compound 1 of any one of claims 11 to 16, or use of the pharmaceutical composition of any one of claim 10, 17, and 18, in the manufacture of a medicament for treating a disease or disorder, wherein the disease or disorder is selected from the group consisting of T1D, T2DM, pre-diabetes, idiopathic T1D, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea, obesity, eating disorders, weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, NASH with fibrosis, cirrhosis, hepatocellular carcinoma, cardiovascular disease, atherosclerosis, coronary artery disease, peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson's Disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer's Disease,

schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn's disease, colitis, irritable bowel syndrome, Polycystic Ovary Syndrome, and addiction.

20. The use of claim 19, wherein the disease or disorder is selected from obesity, NAFLD, NASH, NASH with fibrosis, T2D, and a cardiovascular disease.

21. The crystalline form of tris salt of Compound 1 of any one of claims 1 to 9, the amorphous form of tris salt of Compound 1 of any one of claims 11 to 16, or the pharmaceutical composition of any one of claim 10, 17, and 18, for use in therapy.